Pharmaceutical formulation of odevixibat

US11801226B2 · kind B2 · utility

Assignee

• ALBIREO AB · SE

Inventors

• Eva Byröd · Mölndal, SE
• Per-Göran Gillberg · Timrå, SE
• Anna-Maria Tivert · Gothenburg, SE
• Rikard Bryland · Bunkeflo, SE
• Ann-Charlotte Dahlquist · Lund, SE
• Jessica Elversson · Dalby, SE
• Nils Ove Gustafsson · Löddeköpinge, SE
• Robert Lundqvist · Hälsö, SE
• Ingvar Ymen · Boo, SE
• Martin Bohlin · Stockholm, SE

Key dates

• Filing date: Dec 7, 2020
• Grant date: Oct 31, 2023
• Expiry date: Dec 7, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.